2027年までの欧州医薬品連続製造市場予測 - 新型コロナウイルス感染症の影響と製品別地域分析（統合システム、半連続システム、制御）。アプリケーション (最終製品製造、API 製造);エンドユーザー (本格的な製造会社、研究開発部門);そして、国
No. of Pages: 159 | Report Code: TIPRE00013273 | Category: Life Sciences
No. of Pages: 159 | Report Code: TIPRE00013273 | Category: Life Sciences
製薬業界における連続製造は、生産技術に関する技術の進歩の結果です。過去数年間、製薬業界ではバッチ製造という伝統的な方法が採用されてきました。しかし、技術の発展により品質の向上による大量生産が加速し、医薬品の回収やリコールなど多くの主な原因に対処することができました。製薬業界は最近、製造業務を改善し維持するためのオプションとして連続製造を認識し始めています。
300 社を超える医薬品連続製造会社があり、ミズーリ、コロンビア、カンザス、マンハッタンなどの地域には、
ヨーロッパの医薬品連続製造市場2018年の3億4,241万米ドルから、2027年には7億9,950万米ドルに達すると予想されています。市場は2019年から2027年にかけて10.0%のCAGRで成長すると予想されています。市場の成長を促進する要因には、医薬品不足の増加が含まれます。ただし、医薬品製造に伴う高コストは市場の成長に悪影響を与える可能性があります。
製品別では、統合システムセグメントが2018年の欧州医薬品連続製造市場で最大の市場シェアを占めました。アプリケーションベースでは、最終製品製造セグメントが2027年までに医薬品連続製造市場で最大の市場シェアを保持しました。
レポートに含まれる医薬品連続製造市場に関する主要な一次および二次情報源の一部は、疾病管理予防センター (CDC)、国防研究開発機関です。 (DRDO)、Functional Genomic and Computational Assessment of Threat (Fun GCAT) など。
< strong>
• ヨーロッパ
Strategic insights for Europe Pharmaceutical Continuous Manufacturing involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 342.41 Million |
| Market Size by 2027 | US$ 799.50 Million |
| Global CAGR (2019 - 2027) | 10.0% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By 製品
|
| Regions and Countries Covered | ヨーロッパ
|
| Market leaders and key company profiles |
The regional scope of Europe Pharmaceutical Continuous Manufacturing refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Pharmaceutical Continuous Manufacturing Market is valued at US$ 342.41 Million in 2018, it is projected to reach US$ 799.50 Million by 2027.
As per our report Europe Pharmaceutical Continuous Manufacturing Market, the market size is valued at US$ 342.41 Million in 2018, projecting it to reach US$ 799.50 Million by 2027. This translates to a CAGR of approximately 10.0% during the forecast period.
The Europe Pharmaceutical Continuous Manufacturing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Pharmaceutical Continuous Manufacturing Market report:
The Europe Pharmaceutical Continuous Manufacturing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Pharmaceutical Continuous Manufacturing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Pharmaceutical Continuous Manufacturing Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Pharmaceutical Continuous Manufacturing Market
